International Conference on Drug Discovery And Translational Medicine 2021

“Advancing Precision Medicine with Emerging Technologies: Bridging Gap Between Academia and Industry.” 

Pre-Conference: 7th December 2021
Conference: 8th – 9th December 2021

One of the most anticipated events
in the year 2021

In keeping abreast with the recent emergence of innovative technologies in PM, the organisers have set the conference theme as “Advancing Precision Medicine with Emerging Technologies: Bridging Gap Between Academia and Industry.”

Important Dates

1st Mar 2021

Call For

31st Jul 2021

Abstract Submission

31st Aug 2021

Early Bird
Registration Deadline

31st Oct 2021

Normal Rate
Registration Deadline

7th Dec 2021

Online Pre-Conference Workshops

8-9th Dec 2021

Virtual Conference

About ICDDTM’21

Precision medicine (PM) is significantly changing the way therapies are being developed, benefiting patients, the pharmaceutical industry, and the society.

The Malaysian Association of Cancer Research (MACR), which was established in 2017, quickly saw the importance of PM and aspired to create a global platform for sharing of recent research findings of this field in relation to drug discoveries and translational medicine.

Building upon the success of the inaugural International Conference of Drug Discovery and Translational Medicine (ICDDTM’18), which had attracted delegates from local and abroad, MACR and its collaborators will once again join hands in organising the 2nd ICDDTM’21 from 7th – 9th December 2021.

In keeping abreast with the recent emergence of innovative technologies in PM, the organisers have set the conference theme as “Advancing Precision Medicine with Emerging Technologies: Bridging Gap Between Academia and Industry.”

The conference will feature its plenary and invited talks based on four major areas:
– Cancer
– Microbiome therapy
– Mental health/neurodegeneration
– Stem cell therapy

and one special topic on COVID-19.

A total of 6 conference tracks have been identified for oral and poster presentations:
– Cancer
– Cell therapy
– Inflammatory diseases
– Mental health/neurodegeneration
– Metabolic diseases
– Miscellaneous

Why you should attend the conference?

ICDDTM’18, the predecessor of ICDDTM’21, was a success, attracting 270 participants from local and overseas universities and institutes. The ICDDTM’18 organising committee had also worked hard to assemble a team of 18 well-known speakers from:

  • University of Oxford, UK

  • University College London, UK

  • University of Nottingham, UK

  • Cancer Research UK-Therapeutic Discovery Laboratories, UK

  • Royal College Surgeons in Ireland, Ireland

  • National University of Singapore, Singapore

  • National Cancer Centre, Singapore

  • Bioinformatics Institute, A*STAR, Singapore

  • Kanazawa University, Japan

  • Center for Life Science Technologies, RIKEN, Japan

  • Mahidol Oxford Tropical Medicine Research Unit, Thailand

  • University of Malaya, Malaysia

  • Universiti Sains Malaysia, Malaysia

  • Universiti Putra Malaysia, Malaysia

  • Kuala Lumpur Hospital, Malaysia

ICDTTM’18 had garnered very positive feedback from the participants, with many of them praising the:

  • Renowned & knowledgeable speakers

  • Interesting & informative talks

  • Diversity of topics covered by the conference

  • Translation of cutting-edge science into medical practice

  • Plenty of networking opportunities

  • Great food and venue

We foresee that ICDDTM’21 will be equally enjoyable. So, we look forward to seeing you there!

Who Should Attend


Clinician scientists

Health policy makers

Medical doctors

Industry players


Postdoctoral fellows


Science enthusiasts



Undergraduate & postgraduate students

Invited Speakers

(Director of The N.1 Institute for Health)
Personalized medicine & use of nanodiamonds in drug delivery
National University of Singapore, Singapore

(Professor of Emergency Medicine)
Use of artificial intelligence to predict human behaviour, HIV treatment, & substance abuse treatment
University of Massachusetts Medical School

(Professor of Medicine)
Gene & stem cell therapy, experimental haematology, & molecular biology
University of Sydney, Australia

(Research Group Head, Microbiota & Systems Biology Laboratory)
The impact of gastrointestinal microbiota on disease & health
Hudson Institute of Medical Research, Australia

(Co-Principal Investigator)
Glioma-propagating cells & chemoresistance
Neuro-Oncology Research Laboratory, National Neuroscience Institute, Singapore

(Professor of Neuroscience and Mental Health)
Neurotransmitter release from neurons & optogenetic mapping of brain circuitry
Nanyang Technological University, Singapore

(Director of the Carney Centre for Pharmacogenomics)
Psychiatric genetics, pharmacogenomics, & the genetics of complex diseases
University of Otago, Christchurch

(Senior Technical Consultant)
European Wellness

(Consultant Physician & Gastroenterologist)
Therapy of inflammatory bowel disease & colorectal cancer
UKM Medical Centre, Malaysia

(Director of Centre for Drug Research)
Behavioral interventions & medication use
Universiti Sains Malaysia, Malaysia

(Principal Investigator)
Cell signalling, interfacial interactions, & allostery 
Gorfe Research Group, University of Texas McGovern Medical School-Houston, USA

(Director of University of Malaya Medical Centre & Senior orthopaedic consultant)
Biomechanics, cartilage biology, & stem cell technology
Department of Orthopaedic Surgery, University of Malaya Medical Centre

(Medical Director – Clinical Trials Division)
Herbal pharmaceuticals

2nd Announcement ICDDTM’21

ICDDTM’21 Symposium

(Virtual Events – Free Access)